Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

Abstract Compared to chemotherapy, promising results have been obtained by blocking the PD-1 pathway using antibodies that inhibit programmed cell death protein 1 (PD-1) or programmed cell death protein ligand 1 (PD-L1). Furthermore, global researchers and doctors are exploring how to optimize this...

Full description

Bibliographic Details
Main Authors: Si-Yang Liu, Yi-Long Wu
Format: Article
Language:English
Published: BMC 2017-07-01
Series:Journal of Hematology & Oncology
Subjects:
PD-1 inhibitor
PD-L1 inhibitor
Clinical trials
China
Online Access:http://link.springer.com/article/10.1186/s13045-017-0506-z

Internet

http://link.springer.com/article/10.1186/s13045-017-0506-z

Similar Items